share_log

华海药业(600521.SH):“华海转债”预计触发转股价向下修正的条件

Huahai Pharmaceutical (600521.SH): “Huahai debt conversion” is expected to trigger a downward correction in the conversion price

Gelonghui Finance ·  Mar 3, 2023 17:45

Gelonghui March 3rd 丨Huahai Pharmaceutical (600521.SH) announced that as of March 3, 2023, the closing price of the company's shares had been below 80% of the current conversion price for at least 10 trading days out of 30 consecutive trading days. “Huahai Convertible Bonds” are expected to trigger downward revision conditions in the conversion price. If the condition is triggered, the company will hold a board of directors on the day the condition is triggered to review and decide whether to revise the conversion price and promptly fulfill the obligation to disclose information.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment